This Markov model-based study was conducted to inform the NICE guideline on diabetic retinopathy by assessing the lifetime cost-effectiveness of various anti-VEGFs and PRP (alone or in combination with anti-VEGF) for treating people with PDR without DMO based on two different treatment effect scenarios. The gene discussed is VEGFA; the disease is diabetic retinopathy.